Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

BACKGROUND: Sevelamer is an alternative to calcium carbonate for the treatment of hyperphosphatemia among non-dialysis dependent patients with chronic kidney disease (CKD). Although some studies show that it may reduce mortality and delay the onset of dialysis when compared to calcium carbonate, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Hai V., Bose, Saideep, Finkelstein, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848865/
https://www.ncbi.nlm.nih.gov/pubmed/27121505
http://dx.doi.org/10.1186/s12882-016-0256-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848865/
https://www.ncbi.nlm.nih.gov/pubmed/27121505
http://dx.doi.org/10.1186/s12882-016-0256-0

Ejemplares similares